Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : TaiGen Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TaiGen Enters Exclusive License Agreement with YSP
Details : Under the agreement, Y.S.P. will develop and commercialize TaiGen's new small molecule drug, TG-1000, a virus replication inhibitor, for infections, in Malaysia and Singapore.
Brand Name : TG-1000
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 10, 2023
Lead Product(s) : TG-1000
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : TaiGen Biotechnology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?